Good afternoon, and welcome to Oncolytics Biotech Second Quarter 2024 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Jon Patton, Director of Investor Relations and Communication. Please go ahead.

Thank you, operator. Earlier today on Oncolytics issued a press release providing recent operational highlights and financial results for the second quarter of 2024. A replay of today's call will be available on the Events section of the Oncolytics website. After remarks from company management will open the call for Q&A. As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, including statements regarding the company's mission, strategy and milestones, the company's belief as of the potential and mechanism of action of pelareorep as a cancer therapeutic. Our belief that we are positioned to execute on our key priorities and reach multiple milestones throughout the second half of the year and into 2025. Our potential registrational opportunities for pelareorep anticipated timing of the release of additional data, our cash runway, and other statements related to anticipated developments in the company's business. These statements are based on management's current expectations and beliefs and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or expectations implied by these forward-looking statements. In any forward-looking statements, which are Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis. But there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated intellectual property protection, financial projections, actions by regulatory agencies, and those other factors detailed in the company's filings with SEDAR and the SEC. Oncolytics does not undertake any obligation to update these forward-looking statements except as required by applicable laws. Joining me to discuss the substantial progress we made during the second quarter are a few members of the management team, including Chair of Oncolytics' Board of Directors, and Interim CEO, Wayne Pisano; Chief Medical Officer, Dr. Tom Heineman; Chief Financial Officer, Kirk Look; Vice President, Business Development, Christophe Degois. And with that, it's my pleasure to turn the call over to Wayne. Wayne?

Thank you, John. Good afternoon. I appreciate everyone taking the time to join us today. So I know you are accustomed to our CEO, Matt Coffey leading these presentations. Personally and on behalf of the Board, I'd like to wish Matt a swift recovery. In the interim, the board and I are highly confident in our tenured executive team's ability to continue executing our mission, achieve our strategic priorities, and deliver on our long-term goals, and ultimately, bringing pillar we are up to patients with cancer. Following my brief introduction, Tom will provide an update in the clinical advancements. Christophe will discuss recent collaborations and partnership opportunities. Kirk will review the financials, and finally, we will end by taking your questions. In the second quarter of 2024, we continue to make excellent progress in advancing our potentially leading immunotherapeutic agent, pelareorep or pela, as we often refer to it. We believe we are well-positioned to execute on our key priorities and reach multiple milestones for the second half of the year and into 2025. Now, before Tom provides a comprehensive update on our progress and how recent activities continue our mission to improve the lives of people with cancer, I would like to highlight a few important advancements. Notably, we held an extremely productive Type C meeting with the FDA and we are able to communicate what we consider to be the optimal path appellate and breast cancer going forward. With input from the agency, we were able to align our key elements for the next steps we plan to take and are bolstered by compelling data from two randomized breast cancer studies showing the benefit of pela combined with paclitaxel compared with paclitaxel monotherapy. This gives us confidence in pela's potential to demonstrate a clinically meaningful benefit in a…

Thank you, Wayne. As a reminder, pela is an intravenously delivered immunotherapeutic agent that acts systemically inducing anti-cancer immune responses and promoting an inflamed tumor phenotype that is turning cold tumors hot. This allows the anti-tumor immune cells induced by pela to attack the cancer. As Wayne mentioned, we are currently focused on advancing pela toward registrational studies in breast and pancreatic cancer. We have exciting data and other indications like anal cancer that could eventually lead to additional registrational opportunities. But for today, we'll just focus on breast and pancreatic cancer. Starting with our breast cancer program. I'd like to touch on two topics. Our recent productive Type C meeting with the FDA and the anticipated BRACELET-1 study survival results. In June, we provided a recap of our Type C meeting with the FDA. We had a very productive and helpful discussion with the agency that provided valuable guidance on our proposed registration enabling study. One, perhaps underappreciated takeaway was that the FDA endorsed progression-free survival as the primary endpoint of the study with overall survival as a secondary endpoint. Having progression-free survival as the primary endpoint mirrors the path taken by Pfizer for the initial approval of Ibrance based on the PALOMA-1 study and could save substantial development time by allowing us to reach the potential registrational endpoint sooner. The patient population for the registrational study is anticipated to include patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate therapy. Our de-risk breast cancer program builds on compelling data and key learnings from two prior randomized studies, BRACELET-1 and IND-213, which demonstrated clinically meaningful benefit in patients who were treated with pela and paclitaxel compared to paclitaxel alone. I should also mention that we have translational data from the AWARE-1…

Thank you, Tom. I'm excited to join the team and see a real opportunity for pela and Oncolytics to make an impact to treatment of cancer, so I'm soon to be here. In the second quarter, we enter into a preliminary collaboration with GCAR, which we believe in score the strength of the growing pela dataset that continues to attract and pick the interest of the clinical oncology community. GCAR is a non-profit corporation, uniting physicians, clinical researchers, advocacy and philanthropic organizations, biotech pharma companies, health authorities, and other key stakeholders in healthcare, because objective is to expedite the discovery and development of treatment for patients with rare and dead diseases. As a sponsor of innovative trials, including master protocols and adaptive platform trials, GCAR is dedicated to the advancements of science by modernizing clinical trials that support more efficient, less costly drug development. We are pleased to partner with GCAR and are honored that pela has been selected that the first therapeutic for evaluation in the plan adaptive trial in pancreatic cancer patients. The selection process was thorough and involved meeting with and presenting our clinical data to multiple pancreatic cancer key opinion leaders. We're working together to finalize a Phase 2/3 master protocol design that will evaluate pela and other investigational therapies for the treatment of pancreatic cancer. GCAR anticipated trial design seek to cut registrational study time and reduce trial costs, spinning up the journey to potentially deliver effective cancer treatment sooner. This strategy, which includes leveraging GCAR extensive investigator network, offers a cost-effective opportunity to enhance our ability to quickly and effectively advance the development of this pela based combination therapy for metastatic pancreatic cancer, a disease with a very high unmet medical need and limited treatment options. Beyond GCAR, we intend to continue to stick strategic opportunities to collaborate and maximize therapeutic and commercial potential of pela. We have an ongoing dialogue with current and potential collaborators and believe additional data updates will continue to strengthen our value proposition. I will now turn the call over to Kirk to review the financial results for the second quarter of 2024. Kirk?

Thanks, Christophe, and good afternoon, everyone. I'd like to briefly run through our financial results for the second quarter of 2024, which will be provided in Canadian dollars, unless otherwise noted. A full summary of our financial results can be found on the investor section of our website under filings and reports, or in the press release issued earlier this afternoon. We continue to be cognizant of our cash resources and make the necessary investments to progress pela’s development while ensuring we have funds needed to reach critical milestones. As of June 30, 2024, the company reported $24.9 million in cash and cash equivalents with a projected cash runway into 2025. Net cash used in operating activities for the six months ended June 30, 2024 was $14.3 million compared to $16.3 million for the six months into June 30, 2023. The change reflected non-cash working capital changes partly offset by higher net operating activities in 2024. Now, general and administrative expenses for the second quarter of 2024 were $3.4 million, consistent with $3.5 million for the second quarter of 2023. Research and development expenses for the second quarter of 2024 were $4.6 million compared to $3.7 million for the second quarter of 2023. The increase was primarily due to higher clinical trial expenses, including BRACELET-1, data analysis, and the GCAR collaboration and higher share-based compensation expenses. The increase was partly offset by lower production run and process and analytical development activities in manufacturing. The net loss for the second quarter of 2024 was $7.3 million compared to a net loss of $7.4 million for the second quarter of 2023. The basic and diluted loss per share was $0.10 per share in the second quarter of 2024, compared to a basic and diluted loss per share of $0.12 in the second…

[Operator Instructions] And we will now take our first question. This comes from the line of Louise Chen from Cantor.

This is [Kirby] on for Louise from Cantor. First, can you remind us of the size of the commercial opportunity for pela and HR+/HER2- metastatic breast cancer? And second, what would your registration trial design look like?

Thanks for the questions, Kirby. First, I'll turn it over to Christophe to speak to the market.

I mean this is a very changing environment with obviously some ADCs and to in particular making some obviously some changing a lot this market and based on recent data. So we're currently the process of updating the commercial opportunity. And I think in the next call we'll be able to provide more detail. There's still a significant commercial opportunity if you think about the way NO2 is going to be used in this patient. Obviously, they're going to -- they're not approved yet, but I think it's very likely that they would come right after the [indiscernible] therapy. But unfortunately, as you know this patient will still relapse and you'll need a subsequent line of treatments. And we believe, there's a significant commercial opportunity in NO2 failures. And also, we need to think, consider the patient will not be eligible to NO2 because of very low O2 levels or other condition that may prevent the use of an ADC with these patients.

And I'll ask Tom to respond to the plan.

Yes. So we expect to move forward with our next trial in the form of a registration enabling large Phase 2 study with a primary endpoint of progression-free survival, and in the population that Christophe actually described, which is patients who have either failed antibody-drug conjugate therapy following progression on hormonal therapy, or patients for whom antibody-drug conjugate therapy is inappropriate or who cannot tolerate such agents. So we -- and this study would allow us with two opportunities to win. If it meets a high level of significance for the investigational arm, it would put us in the position of applying for an accelerated approval. And at a very minimum, it would substantially de-risk any subsequent trial that we would conduct to confirm the efficacy of the combination therapy.

And the next question comes from the line of John Newman from Canaccord.

I also had a question about the registration enabling study for pelareorep, and breast cancer. I'm assuming that most of the patients, if not all the patients enrolling in the study will have previously been treated with an ADC. Is there any specificity as to which ADC? And then the second question that I had was just in terms of the geography of the study, would this be primarily a U.S. based study or would you also include patients from Europe?

Yes. John, I can, from here I can comment on that. So I think as Christophe said, the treatment approach in patients as it relates to the antibody-drug conjugates is still evolving. So I don't think anyone can say with precision exactly what proportion of patients in our study would've failed antibody-drug conjugate therapy, but I think it's very, very reasonable to assume that the majority of them would've received antibody-drug conjugate therapy. There will be patients who are not appropriate for antibody-drug conjugate therapy or who take it for a short period of time and cannot tolerate it. So there will be patients who come into the study through other pathways. But at present, the data that are available in the population we're looking at would suggest that the antibody-drug conjugate therapy that would be most in play. That is to say the patient -- the therapy that patients would have failed before coming into our study would be in HER2. That's the agent for which the data currently exists suggesting a solid benefit immediately following the failure of hormonal therapy. On the geography, yes. I'm sorry. This study -- we would anticipate that this study would be, have a substantial enrollment in North America, of course. And we're currently evaluating possible other geography for enrollment. It seems reasonable to expect that there would be sites in some of the major Western European countries, for example. And beyond that, we need to consider our option.

And the next question comes from the line of Soumit Roy from Jones Research.

Possibly a question for Tom. The BRACELET-1 trial, have you disclosed P-Value or was it too small of a cohort size? And second question is for the Phase 2/3 registration trial in breast cancer, do you expect potentially a portion of patients being treated with ADC as the only major variable difference between BRACELET-1 and the Phase 2/3? Or do you see other changes could be there? The differences between BRACELET and the Phase 2/3?

We have [indiscernible] P-Value for the PFS comparison. And the comparison, the P-value for the comparison between paclitaxel and the paclitaxel plus pelareorep [indiscernible] was 0.03. So it was less significant at less than the 0.05 level. And with regard to the differences in the BRACELET population, yes. I mean, I think you're right. We would be enrolling patients in this study as discussed already, who have failed ADC therapy, which were not enrolled in BRACELET because they simply did not exist at that time. But otherwise the patient population would be essentially identical to the BRACELET patient population.

A quick follow-up, do you expect to do any sub-analysis separated out those patients with prior ADC in Phase 2/3, or how are you thinking of what --

We haven't formalized our analysis plans to that level, but I'm sure that we would be looking at any distinctions between significant population groups within any randomized study.

And the next question comes from the line of Michael Okunewitch from Maxim Group.

I just want to a see if you could help clarify the nature of the additional registrational opportunity that you're saying could emerge from cohort 5 of the GOBLET study. Is there an expectation here that you could file for accelerated based on that data, or are you referring to the ability to launch a second registrational study based on that data? A – Tom Heineman : Yes, so the data that we're generating in cohort 5 of the GOBLET study, we view that as a kind of signal finding proof-of-concept data. We would not expect that those data would support in and of themselves an accelerated approval. However, as we are planning to move forward with the other combination, the pela plus the gemcitabine, nab-paclitaxel in through the collaboration with GCAR, which it would be in a registrational approach. And it is certainly possible if the cohort 5 results look, good and turn out the way we hope and expect they will, that combination could be evaluated, for example, in the platform study such as what we're doing with GCAR already or through some other mechanism.

And then one other for me, and I'll hop back in the queue, I wanted to see if you had any expectations on the size of the potential pivotal study in breast cancer that you'd need based on the prior PFS data that you have in pass for pela in this setting? A – Tom Heineman : Yes, what we're looking at, I mean, the model that we're following is very similar to the approach that was used by Pfizer, for example, for their initial licensure of Ibrance and then subsequently, by Daiichi for the initial licensure of Enhertu. So what we'd be looking at would be a study of sub 200 patients, 180, 200 patients, somewhere in that order of magnitude.

Thank you very much, and wishing for a speedy recovery from that.

The next question comes from the line of Rahul Sarugaser from Raymond James.

Also, I'll just reiterate Jason's point about wishing a speedy recovery for Matt, but also following up from Jason's question. Talking about the now that you've, you're through the Type C meeting and you're looking at setting up the breast cancer trial, these patients are effectively going to be second, third line after selling hormone or potentially an ADC. So perhaps you can let us know, give us your, give us a sense of your confidence on patient recruitment, the number of sites you, you'll need to be able to fill the study and how fast you think you'll be able to recruit given that we think that this going to be a relatively competitive patient group. A – Tom Heineman : Well, I mean, I think that keep in mind that we are not in for the breast cancer, the next study in breast cancer, we are not planning to compete with in Enhertu, right? We would be coming in and recruiting patients who can either not receive in Enhertu, for example, or who have failed in Enhertu. And for those groups, the only options really available are traditional chemotherapy for the large -- majority of those patients. And so actually to the contrary, I suspect that there will be a pretty high demand for patients' participation in a study that offers something with clear earlier data that improves upon standard of care chemo, if you see what I'm saying. In other words, I think there'll be plenty of patients who would be looking for a better options than what would otherwise be available. So I would anticipate that the enrollment into the study would be reasonably straightforward.

And now just as a follow on pivoting to the GOBLET study in PanCAN, could you perhaps give us a sense for the destination at which point partners might be interested? Is there a set of outcomes or interim readout that you think would engender that interest?

That's a challenging one. Our expectation is on the pancreatic cancer side of things is that we will -- as we see the GCAR study the first part of the adaptive design study read out, is that we'll be able to leverage that and go out specifically with that information to speak to potential partners. What we do find interesting on the cohort 5, on the GOBLET side of things with the modified FOLFIRINOX combination is we think that that can be quite interesting because if it shows similar data as to cohort 1 with the gem nab-paclitaxel combination, we think that we have an opportunity to capture a large percentage of the pancreatic cancer treatment market in this particular stage. So, we will take advantage of that data and those results, so when they come out and then we'll start to obviously outreach towards partners at that time. That said, though, prior to that data coming out, we will have and things are progressing as expected on the BRACELET overall survival analysis. And so that's happening much quicker. And so we'll be looking to perform some meaningful outreach with that information in hand subject to the results earlier than what we see out of the pancreatic cancer cohorts.

You answered my other questions. So thanks very much, Kirk. Really appreciate it. We'll get back in the queue and best wishes to Matt.

Thank you. That concludes our Q&A session for today. And I will now hand back the call to Kirk Look, please go ahead, sir.

Thank you everyone and for all that are participating in today's call and for your interest in Oncolytics Development. We continue to be passionate about improving cancer treatment options for patients, and we're taking the necessary steps to bring pela to patients by working with our regulators, our clinical collaborators, and the investigators running our studies. We really look forward to our next opportunity to provide another update on our progress and sharing our plans for the rest of the year and into 2025. I'll end our prepared remarks by wishing everyone a great evening. Thanks very much.

Thank you. This concludes our conference for today. Thank you all for participating. You may now disconnect your lines.